Reducing hospitalization in elderly influenza vaccine recipients
AssigneeSeqirus UK Limited
InventorNicola Groth
Life of this patent
Estimating the term…
Abstract
Compared to an unadjuvanted vaccine, an adjuvanted influenza vaccine can reduce by almost a quarter the risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) in elderly recipients. Thus the invention provides a method for immunizing an elderly subject by administering an adjuvanted influenza vaccine, whereby the subject's risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) is reduced relative to an elderly subject who receives an unadjuvanted influenza vaccine.
Claims21
A method for reducing an elderly subject's incidence of hospitalization for influenza respiratory illness, comprising administering at least a priming, first dose of a tetravalent influenza vaccine adjuvanted with a squalene-containing oil-in-water emulsion to the elderly subject in consecutive influenza seasons, whereby the elderly subject's incidence of hospitalization for influenza respiratory illness is reduced relative to an elderly subject who receives an unadjuvanted influenza vaccine, wherein the elderly subject who receives the adjuvanted tetravalent influenza vaccine is receiving immunosuppressive therapy and ranges from 65-100 years old;
- further wherein the recipient of the adjuvanted influenza vaccine does not receive an unadjuvanted influenza vaccine during any of the consecutive influenza seasons.
A method for reducing an elderly subject's incidence of hospitalization for influenza respiratory illness, comprising administering at least a priming, first dose of a tetravalent influenza vaccine adjuvanted with a squalene-containing oil-in-water emulsion to the elderly subject in consecutive influenza seasons, whereby the elderly subject's incidence of hospitalization for influenza respiratory illness is reduced relative to an elderly subject who receives an unadjuvanted influenza vaccine, wherein the elderly subject who receives the adjuvanted tetravalent influenza vaccine is receiving immunosuppressive therapy and ranges from 65-100 years old, and wherein the concentration of squalene in the oil-in-water emulsion ranges from 2 to 10% by weight;
- further wherein the recipient of the adjuvanted influenza vaccine does not receive an unadjuvanted influenza vaccine during any of the consecutive influenza seasons.
Dependencies are inferred from the claim text.